Vericel (VCEL) Assets Average (2011 - 2026)
Vericel (VCEL) posted Assets Average of $494.2 million for Q2 2026, up 1.53% sequentially from $486.8 million in Q1 2026, and up 14.91% YoY from $430.1 million in Q2 2025.
Analysis
Vericel (VCEL) Assets Average (2011 - 2026) Analysis & Trends
Vericel has reported Assets Average for 16 years, with the latest figure at $494.2 million in Q2 2026.
- Quarterly Assets Average rose 14.91% year-over-year to $494.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $494.2 million (up 14.91% YoY) and the FY2025 annual result came in at $460.3 million, up 17.08% from the prior year.
- Assets Average improved to $494.2 million in Q2 2026 per VCEL's latest filing, from $486.8 million in the prior quarter.
- Over five years, Assets Average peaked at $494.2 million in Q2 2026 and troughed at $242.0 million in Q1 2022.
- A 5-year average of $359.5 million and a median of $361.0 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2024: Assets Average climbed 10.48% in 2022, then jumped 32.01% in 2024.
- Over 5 years, Assets Average stood at $260.5 million in 2022, then climbed by 28.94% to $335.9 million in 2023, then gained by 22.53% to $411.6 million in 2024, then grew by 14.35% to $470.6 million in 2025, then grew by 5.02% to $494.2 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $494.2 million, $486.8 million, and $470.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | 494.25 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 494.25 Mn |
| Mar 31, 2026 | 486.80 Mn |
| Dec 31, 2025 | 470.62 Mn |
| Sep 30, 2025 | 444.44 Mn |
| Jun 30, 2025 | 430.10 Mn |
| Mar 31, 2025 | 428.65 Mn |
| Dec 31, 2024 | 411.56 Mn |
| Sep 30, 2024 | 383.62 Mn |
| Jun 30, 2024 | 366.75 Mn |
| Mar 31, 2024 | 355.16 Mn |
| Dec 31, 2023 | 335.89 Mn |
| Sep 30, 2023 | 314.42 Mn |
| Jun 30, 2023 | 287.90 Mn |
| Mar 31, 2023 | 269.05 Mn |
| Dec 31, 2022 | 260.51 Mn |
| Sep 30, 2022 | 246.42 Mn |
| Jun 30, 2022 | 242.55 Mn |
| Mar 31, 2022 | 242.00 Mn |
| Dec 31, 2021 | 233.92 Mn |
| Sep 30, 2021 | 223.04 Mn |